Network meta-analysis combining individual patient and aggregate data from a mixture of study designs with an application to pulmonary arterial hypertension

Table 1 Summary statistics of patients in IMPRES RCT

Baseline therapy	Add-on Therapy	Size¶	Drop out§	Mean 6MWD improvement	Mean age	Prop male	Mean STATUS	Mean 6MWD baseline	Mean PVR
ERA + PDE5i	Placebo*	23	4	2.54 (16.25)	50.30	0.30	2.96	342.07	1157.0
ERA + PDE5i	Imatinib	20	12	43.7 (14.27)	50.15	0.10	2.60	328.95	1282.1
ERA + Pr	Placebo	8	2	7.81 (14.36)	37.00	0.25	2.38	381.56	1146.6
ERA + Pr	Imatinib	10	5	48.3 (16.12)	47.20	0.00	2.80	331.60	1071.9
ERA + PDE5i + Pr	Placebo	33	8	−8.27 (10.47)	47.03	0.18	2.73	355.79	1176.6
ERA + PDE5i + Pr	Imatinib	27	15	33.37 (11.54)	47.74	0.19	2.85	360.70	1232.5
PDE5i + Pr	Placebo	16	4	36.03 (10.53)	43.19	0.06	2.56	358.72	1193.9
PDE5i + Pr	Imatinib	9	5	40 (14.59)	53.00	0.11	2.78	380.56	1050.8

*ERA is any endothelin receptor antagonist, PDE5i is phosphodiesterase 5 inhibitor, and Pr is prostacyclins (oral, inhaled, intravenous or subcutaneous).
¶ Group size was number of patients taking 6MWD test at baseline and 24 weeks.
§ Dropout is number of patients dropping out of the study between baseline and 24 weeks. Dropout due to death, adverse events, consent withdrawal, protocol deviation, abnormal laboratory result, administrative error, or adverse reaction to study drug.